Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin

References

• American Heart Association. Heart Disease and Stroke Statistics -- 2009 Update. Dallas, TX: American Heart Association, 2009
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-89
   PubMed Web of Science ®Google Scholar
• Shepard J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range to initial cholesterol levels. N Engl J Med 1998;339:1349-57
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Eng J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Bairney Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report on the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA news release: FDA approves first generic simvastatin. June 23, 2006 [updated July 5, 2006]. Available at: http://www.fda.gov/bbs/topics/News/2006/NEW01394.html [Last accessed 4 May 2009]
   Google Scholar
• Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:852-7
   Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar
• Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and national cholesterol education program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006;26:469-78
   PubMed Web of Science ®Google Scholar
• IMS Health. NPA (National Prescription Audit) Market Dynamics. Norwalk, Conn, USA: August 2009
   Google Scholar
• Fox KM, Gandhi SK, Ohsfeldt RL, et al. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database. Clin Ther 2007;29:2385-94
   PubMed Web of Science ®Google Scholar
• Foley KA, Simpson RJ, Crouse JR, et al. Effectiveness of statin titration of low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92:79-81
   PubMed Web of Science ®Google Scholar
• Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996;100:605-10
   PubMed Web of Science ®Google Scholar
• WellPoint: press releases [Internet]. Indianapolis. WellPoint Expands GenericSelect(R) Program to Include Generic Version of Blockbuster Cholesterol-Lowering Treatment Zocor(R), 19 March 2007. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=130104&p=irol-newsArticle_general&t=Regular&id=975089& [Last accessed 22 April 2009]
   Google Scholar
• Reuters: latest news [Internet]. St. Louis. Express Scripts Announces Major Consumer Health Initiative Inspired by $600 Million Savings, 15 April 2008. Available at: http://www.reuters.com/article/pressRelease/idUS148220+15-Apr-2008+BW20080415 [Last accessed 22 April 2009]
   Google Scholar
• Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. PharmacoEconomics 2004;22(Suppl. 3):13-23
   PubMed Web of Science ®Google Scholar
• Usher-Smith JA, Ramsbottom T, Pearmain H, et al. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting. Int J Clin Pract 2007;61:15-23
   PubMed Web of Science ®Google Scholar
• Usher-Smith JA, Ramsbottom T, Pearmain H, et al. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008;62:480-4
   PubMed Web of Science ®Google Scholar
• Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625-9
   PubMed Web of Science ®Google Scholar
• Kamat SA, Gandhi SK, Davidson M. Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals. Curr Med Res Opin 2007;23:1121-30
   PubMed Web of Science ®Google Scholar